Trials
4 active
4 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)”In the company’s words, NCT05521438 on ClinicalTrials.gov
- Tested for
- Netherton Syndrome (4 trials)
- Main trialPhase 2/3
- “This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle”In the company’s words, NCT05521438 on ClinicalTrials.gov
Other drugs for Netherton Syndrome
- BCX17725BioCryst Pharmaceuticals · Phase 1
Coming up3
- 30 DecPhase 2/3 trial completes · ClinicalTrials.gov
- 30 DecPhase 2/3 trial completes · ClinicalTrials.gov
- 31 Jan 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 30 Dec 2025 | Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome | |
| Phase 2/3Recruiting | 30 Dec 2026 | Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | |
| Phase 2/3Recruiting | 30 Dec 2026 | Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome | |
| Phase 2/3Recruiting | 31 Jan 2027 | Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026